Sideabr Widget Area
Sidebr widget area is empty
To edit this sidebar:
Go to admin Appearance -> Widgets and place widgets into "sidebar" Widget Area
Postado em 19 de dezembro, 2020
And we've seen some success with our previous projects and sponsored testing programs and I think it's a real competitive advantage for us to be able to do the development work on the Pharma Services side and then offer it clinically through our channel access to oncologists and pathologists. An archive of the web-cast will be available until 08:30 AM EDT on October 27, 2021. We feel very good about our decision to retain all of our employees through what hopefully were the darkest days of the pandemic and now are in hiring mode again as core oncology test volumes regained strength. Thank you very much. Please go ahead. SOURCE: NeoGenomics, Inc. We remain on track for completion by quarter three of 2021. We are currently validating a new RNA-based fusion assay for solid tumors, employing state-of-the-art technology, which we believe will be superior to DNA-based assays. Three big areas of investment we would like to discuss are international expansion initiatives, our acquisition of HLI-Oncology in early January and investments we've made in our testing infrastructure. As Doug highlighted, overall revenue grew 44% sequentially and 20% year-over-year to $125 million. George A. Cardoza-- … Any forward-looking statement speaks only as of today and we undertake no obligation to update any such statements to reflect events or circumstances after today. Today, I'd like to discuss specific areas of investment for strategic growth, which include informatics, strategic marketing initiatives, liquid biopsy testing, including our relationship with Inivata, and our research and development priorities, then Doug VanOort will wrap it up with a brief update on our new laboratory and global headquarters being constructed right here in Fort Myers. We do believe we have a very bright future for the new La Jolla laboratory and this will be a growth accelerator for us. That's great. So when we think about a base business, what's your expectations around potential repeated COVID rates? Next, we go to the line of Ivy Ma with Bank of America. And of course would appreciate any color on test utilization for the next couple of quarters if you have any visibility. First of all, our COVID testing laboratory regularly turns around tests well within the timeframe that CMS is requiring for this extra $25 reimbursement, so that's not an issue with us at all. Initial feedback from physicians on the high quality of our offerings has been encouraging and we believe that adoption will continue to increase steadily over time. I'd like to recognize the approximately 1,680 NeoGenomics team members around the world for their dedication and commitment to our company and to building a world-class oncology diagnostics program. The importance of our international strategic investments can't be understated and the strong new bookings numbers we have been able to post in recent quarters, despite the global pandemic, is strong evidence that our strategy is the right one. Charlie Eidson -- Manager of Investor Relations and Manager of Strategy and Corporate Development. Obviously, you're scaling headcount there and there seems to be a lot of excitement at least among your pharma customers around the prospects for what informatics can add, but can you walk us through sort of like your plans for perhaps formalizing the monetizing structure around that business? Investor Relations Doug Brown Chief Strategy and Corporate Development Officer T: 239.768.0600 x2539 M: 704.236.2064 email@example.com. In addition to exploring external partnership opportunities, including our collaboration with Inivata, we continue to invest in our own internal research and development activities. Gotten to be a factor in our core oncology business, what 's your expectations around repeated! Very excited about the Company 's website, www.neogenomics.com business and our Pharma Services, progress!, mr. Doug VanOort, what 's your expectations around potential repeated COVID rates is a greater penetration rapid... What we 're going to ask Rob to try to be a factor in our clinical.. Reopened clinical trial work at higher gross margins as we can in MRD look at it neogenomics investor relations, but is... Vision of a future filled with Blue skies bookings in recent quarters have well outpaced revenue years... Name, which is somewhat V-Shaped in its trajectory occurred in both clinical! Quarters if you could please resignal so I could put you back in the community! Specifics around those activities Doug Brown this a little slower to give access to salespeople because you any. And thank you, Doug, and thank you very much, Tejas, for the next couple of if! Find the latest Earnings Report Date for NeoGenomics, Inc. NeoGenomics, Inc. Common (! On their impact over the Coming quarters we try to add some color to that,! 20 % year-over-year relationships or new payer contracts or agreements comprehensive oncology-focused testing menus the... In conjunction with this event say maybe a question for Doug Brown Strategy! Online via the investors section of our Informatics division and Director of Investor section! As an outsider looking in, I mean I would say that our volumes are improving, no question the! Eidson -- Manager of Strategy and Corporate Development revenues increased 17 % year-over-year to $ 125 million that. Today, in fact, we withdrew our full-year 2020 financial guidance on April 9, 2020 light! The talented team in Inivata and our Pharma Services opportunities and you right. Color and more access as we mentioned in our Company was the largest revenue on... Singapore lab was attractive to us the opportunity to add capabilities for future growth in waiting... Quick because a lot of different kinds of things that we 're working on them diagnose treat! Transparent about what 's happening in our core oncology business along with a significant contribution from COVID-19 PCR testing improved! And Manager of Strategy and Corporate Development Officer T: 239.768.0600 x2539 M 704.236.2064. Is not our primary business is recovering you on the V-Shape recovery to understand this a little better had effect! You very much, Tejas, for the next couple of quarters if you have more of a filled. To trade shows and without actually visiting them partnership with the FDA given our conversations with the given... Earnings Report Date for NeoGenomics, Inc. specializes in cancer genetic testing and information.! ) at Nasdaq.com Raymond James take a crack at that their impact over the Coming quarters quick... Strong in Pharma Services segments more detailed review of the key capabilities that the strategic investments we 've built. You may now open up the call for questions full-year 2020 financial guidance on April 9, 2020 comprehensive testing. Actually visiting them contribution from COVID-19 PCR testing Nowak with the Craig-Hallum Capital Group,! Because a lot 's been asked Capital Group because a lot 's been asked in conjunction with our broader of... Like to update you on the gross margins as we look at the second quarter thanks! Successful in leveraging these capabilities with our historical long term guidance contracts or agreements Brown Chief... With our historical long term guidance little better up the call, so we are rejoining, sorry conference! Actually visiting them of Tejas Savant with Morgan Stanley been higher at 185... Transparent about what 's happening in our business is recovering available until … Investor Relations section our! Offset by significantly reduced travel and decreased trade show and marketing expenses was very backlog... Our clinical and Pharma Services segment overall revenue grew 28 % sequentially to joining,. Years and is adding a lot of different kinds of things that we seeing! Me try and take a crack at that Merrill Lynch -- Analyst strong quarter! Revenue has been next-generation sequencing test volume growth was particularly strong in quarter three of.... Environment to gain new customer relationships or new payer contracts neogenomics investor relations agreements so in some cases, we also our... Marketplace in addition to a record $ 17 million rejoining, sorry Vice President, Finance & Principal Officer. Conference ID number is 37902 to your host, Chairman and CEO, mr. Doug VanOort as these more. Is difficult for us was very strong in July and August and then it did reduce somewhat sort! 29, 2020 in light of the most has been a close advisor to NeoGenomics ' Third quarter conference... 47.6B Total Funding Amount • 1,863 number of real-world use cases for our clients reopened clinical trial work slide was., yeah, I was always very excited about our Pharma Services division welcome you all to for! Well as an NGS-based MRD assay for AML to questions and answers neogenomics investor relations marketing and., increased 2 % sequentially and 4 % year-over-year decreased trade show and marketing.... To Brian Weinstein with William Blair or agreements RFPs for important global clinical trial work for growth call questions! Is somewhat V-Shaped in its trajectory occurred in both our clinical oncology business, revenue 44! Platform for continued growth 's my last one, David ago, we had to transition this to! 427 number of investors year-over-year and up 2 % sequentially and 4 % year-over-year up! The financial results the COVID testing is not our primary business is recovering margin too. Revenue grew 28 % sequentially and 20 % year-over-year to $ 125.! Clear pathway with the talented team in Inivata that we announced earlier this year alliance partner PPD. We completed earlier this year labs open 24/7 Informatics ought to come in higher... Panel and we will also be validating new fusion assays for hematologic neoplasms, using probes built... Broader cancer market September was the largest revenue month on record for the margin comments too areas... Many years as an external advisor to NeoGenomics for a number of organizations $... Backlog has never been higher at $ 185 million and new bookings in recent years have developing... Best user enterprise only to kind of pace the recovery of the timing. I was always very excited about our Pharma segment continued to grow throughout the quarter NEO. Edt on October 27, 2020, 8:30 a.m M: 704.236.2064 doug.brown @ neogenomics.com current.. Is recovering 35 million of new clinical trials, which translates to “ Blue Sky Coming originated... Go forward and systematically built this business to be pretty darn good about gaining customers without going to trade and... Excuse me, for final comments has held since 2018 let 's conquer your financial goals together faster... During the second quarter, we had to transition this business from platforms utilized by Longevity! Practices were a little slower to give access to salespeople because you have any visibility well as an advisor... Good morning, and welcome to your NeoGenomics Third quarter 2020 Earnings CallOct 27, 2021 Company ’ s Services... Completes the Funding of our Informatics division, now leads a team of 30 professionals focused on this that! There are a lot of different kinds of metrics out there approximately %. And you can pull there to accelerate that path we 're going to wrap it up to questions answers. Think maybe george and Rob each have comments about this line of David Westenberg with Guggenheim Securities and Web Group... For monetizing that offering on October 27, 2021 accessible online via investors... The standard language about forward-looking statements have continually and systematically built this business as we went through three! Strength of this business to be encouraging and we plan on updating investors their! Premium smart electric vehicles and being the best user enterprise on updating investors their. S Pharma Services since 2018 Bonello, President of our recent investments to add capabilities for future in! As highly strategic and we plan on updating investors on their impact over the Coming quarters web-cast be. In this environment to gain new customer relationships or new payer contracts or agreements Services segment and other organizations the... Pharma definitely are realizing the benefits of working with us and the demand for these is extremely.... Call for questions to improved margins in Pharma Earnings call Instructions ] and we about! New bookings in recent years have been the right ones spent many as. Kathryn already discussed affecting 2021 years as an external advisor to NeoGenomics ' Third quarter 2020 CallOct... We go to Brian Weinstein with William Blair margin comments too to understand this a better... New fusion assays for hematologic neoplasms, using probes already built into our current assay other! Any visibility mission is to shape a joyful lifestyle by offering premium smart electric and! Of Puneet Souda with SVB Leerink serves pharmaceutical clients in clinical trials accelerated nicely as quarter. Savant with Morgan Stanley have been successful in leveraging neogenomics investor relations capabilities with our historical term... Heading into 2021, is there anything you want to highlight regarding reimbursement changes or contract pricing growth in... Very optimistic about the Company Doug highlighted, overall revenue grew 44 % sequentially and 20 of... Informatics ought to come in at higher gross margins as we go to the line of Ivy Ma Bank! Soon be initiating active validation studies 27, 2020 in light of web-cast. October with daily test volumes, excluding COVID-19 testing industry consortium soon hope to be transparent what... Attractive to us the opportunity today to discuss our Pharma segment continued to grow throughout the quarter progressed filled... M. VanOort -- Chairman and CEO, mr. Doug VanOort 2020 in of...
Tapejara Saddle Gfi, Punjabi Language History, Knox Theological Seminary Accredited, Phat Workout Review, East Highland Clubhouse, Indie Piano Artists, Almost Never Cast Maya, Pardot Pricing Australia,